89Zr-Girentuximab
TLX-89Zr-TX-250-001D
Phase 1 other completed
Quick answer
89Zr-Girentuximab for Clear Cell Renal Carcinoma is a Phase 1 program (other) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Telix Pharmaceuticals Ltd
- Indication
- Clear Cell Renal Carcinoma
- Phase
- Phase 1
- Modality
- other
- Status
- completed